NDAORAL-28TABLET
Approved
Jul 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORQUEST FE is an oral contraceptive combining ethinyl estradiol and norethindrone with ferrous fumarate for iron supplementation. It prevents pregnancy through hormonal suppression of ovulation and is used in a 28-day cycle. The ferrous fumarate component addresses iron loss from menstruation, providing dual contraceptive and nutritional benefit.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); expect team restructuring and focus shift toward generic transition planning or brand differentiation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORQUEST FE positions you in mature-product management and commercial optimization rather than innovation-focused roles. Career value derives from managed decline expertise, generic transition strategy, and market access skills as the product approaches loss of exclusivity.
Brand ManagerProduct Manager
Worked on NORQUEST FE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.